Oruka Therapeutics, Inc. (ORKA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Oruka Therapeutics, Inc. (ORKA) closed at USD 76.68 on 2026-10-14, a change of +179.4 % over the past year, with a market capitalization of USD 4.89B.

Oruka Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Oruka Therapeutics, Inc. key figures

Previous close

USD 76.68 (2026-10-14)

1-year change

+179.4 %

Market cap

USD 4.89B

Enterprise value

USD 4.02B

P/E ratio (trailing)

-36.21

P/E ratio (forward)

-25.81

EPS (trailing)

-2.04

EPS (forward)

-2.86

PEG ratio

n/a

Price to book

4.06

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.87

Employees

68

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Oruka Therapeutics, Inc. and compare it with other stocks.